Page 276 - Read Online

in Ch-Np-treated cells, may thus reduce the metastatic Conflicts of interest
ability of cancer cells. There are no conflicts of interest.

As mentioned earlier, CAFs are derived from the tumor by REFERENCES
the process of EMT, which involves loss of intracellular
adhesion. The absence of E-cadherin in control CAFs 1. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA,
supports the process of EMT and loss of intracellular Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL.
adhesion. [5,21] The other important molecular marker, Loss of TGF-beta type II receptor in fibroblasts promotes mammary
VEGF, which plays a role of angiogenesis, was also not carcinoma growth and invasion through upregulation of TGF-
alpha-, MSP- and HGF-mediated signaling networks. Oncogene
affected by Ch-Np treatment. Hence, future studies 2005;24:5053-68.
[22]
have to be done with Ch-Np on CAFs so as to target 2. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells:
E-cadherin and VEGF. Tumor development involves a diabolic liaison driving cancer progression. Cancer Metastasis
a variety of chemokines which are secreted by cancer Rev 2012;31:195-208.
cells. CXCR4, CXCR7, CCR5, and Sdf-1α are some 3. Ha SY, Yeo SY, Xuan YH, Kim SH. The prognostic significance
such chemokines. Prominent expression of CXCR4 in of cancer-associated fibroblasts in esophageal squamous cell
carcinoma. PLoS One 2014;9:e99955.
esophageal cancer has been shown to have a poor long 4. Saito S, Morishima K, Ui T, Hoshino H, Matsubara D, Ishikawa S,
term prognosis and involvement in tumor spread. Aburatani H, Fukayama M, Hosoya Y, Sata N, Lefor AK, Yasuda
[23]
CXCR4 and its ligand, Sdf-1α, were found to be involved Y, Niki T. The role of HGF/MET and FGF/FGFR in fibroblast-
in the metastasis of esophageal cancer in an in vivo derived growth stimulation and lapatinib-resistance of esophageal
model. The role of CXCR7 and CCR5 in esophageal squamous cell carcinoma. BMC Cancer 2015;15:82.
[24]
cancer is poorly understood but in breast cancer they 5. Fu L, Zhang C, Zhang LY, Dong SS, Lu LH, Chen J, Dai Y, Li Y, Kong
are involved in proliferation and metastasis. [25,26] Hence, KL, Kwong DL, Guan XY. Wnt2 secreted by tumour fibroblasts
promotes tumour progression in oesophageal cancer by activation
these chemokines serve as important metastatic genes of the Wnt/-catenin signalling pathway. Gut 2011;60:1635-43.
in the case of esophageal cancer. Down-regulation was 6. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a
noticed in expression of CXCR4, CXCR7, CCR5, and promising system in novel drug delivery. Chem Pharm Bull
Sdf-1α in Ch-Np-treated CAF, implying anti-metastatic 2010;58:1423-30.
activity of Ch-Np. Further support to our hypothesis of 7. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S,
anti-metastatic activity of Ch-Np was provided by the Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma
in cancer progression and prognosis: emphasis on carcinoma-
Scratch Assay in which treated CAFs did not spread in associated fibroblasts and non-small cell lung cancer. J Thorac
the scratched area, indicating loss of metastatic activity. Oncol 2011;6:209-17.
8. Qi LF, Xu ZR, Li Y, Jiang X, Han XY. In vitro effects of chitosan
In conclusion, chitosan is a biopolymer which has been nanoparticles on proliferation of human gastric carcinoma cell line
extensively studied for its ability to encapsulate the MGC803 cells. World J Gastroenterol 2005;11:5136-41.
drug molecule within it. In our study we have shown 9. Zhang Yong-cheng, Wu Xiao-ying, Chen Xiao-lan. Inhibitory effect
of chitosan nanoparticles-mediated HER-2 siRNA on migration of
anti-tumor and mainly anti-metastatic ability of Ch-Np breast cancer cell line SK-BR-3. Chinese Journal of Breast Disease
on esophageal CAF. Decrease in the various genes by (Electronic Edition) 2011 May.” [Online]. Available from: http://
chitosan shows that it is a promising drug molecule in the en.cnki.com.cn/Article_en/CJFDTOTAL-ZHRD201105011.htm
treatment of metastatic cancer. Hence, chitosan should 10. Seluanov A, Hine C, Azpurua J, Feigenson M, Bozzella M, Mao Z,
not be considered only as a carrier of drug molecules but Catania KC, Gorbunova V. Hypersensitivity to contact inhibition
should be considered as a drug itself. Also, in order to provides a clue to cancer resistance of naked mole-rat. Proc Natl
Acad Sci U S A 2009;106:19352-7.
better treat ESCC, it is important to study the stromal cell 11. Kraning-Rush CM, Reinhart-King CA. Controlling matrix stiffness
fraction and its molecular mechanism so as to develop and topography for the study of tumor cell migration. Cell Adh Migr
molecular targeted therapy. Encapsulation of an anti- 2012;6:274-9.
cancer drug within Ch-Np could work as a dual stratagem 12. Potdar PD, D’Souza SB. Ascorbic acid induces in vitro proliferation
against cancer, targeting both cancer and CAFs. Hence, of human subcutaneous adipose tissue derived mesenchymal stem
future clinical and pharmacological studies with Ch-Np cells with upregulation of embryonic stem cell pluripotency markers
need to be done. Oct4 and SOX 2. Hum Cell 2010;23:152-5.
13. Pravin Potdar, Sachin Chaugule. Establishment and molecular
Acknowledgments characterization of breast cancer mesenchymal stem cell line
derived from human non-metastasis breast cancer tumor. Stem Cell
Authors wish to thank Management of Jaslok Hospital Discov 2011;2:21-8.
and Research Center for allowing us to carry out this work 14. Wang YD, Cai N, Wu XL, Cao HZ, Xie LL, Zheng PS. OCT4
at their institute and for their constant support. We also promotes tumorigenesis and inhibits apoptosis of cervical cancer
cells by miR-125b/BAK1 pathway. Cell Death Dis 2013;4:e760.
thank Ms. Keerti Sen for her initial technical work on this 15. Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, Nesland
project. JM, Suo Z. Oct3/4 and Sox2 are significantly associated with an
unfavorable clinical outcome in human esophageal squamous cell
Financial support and sponsorship carcinoma. Anticancer Res 2009;29:1233-41.
Nil. 16. Ha SA, Lee YS, Kim HK, Yoo J, Kim S, Gong GH, Lee YK,
266
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ July 29, 2016 ¦